NASDAQ$PDSB
PDS Biotechnology Corporation · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
PDS Biotechnology reported fourth-quarter and full-year 2021 financial results and provided a business update.
PDS Biotechnology reported a net loss of approximately $16.9 million for the year ended December 31, 2021. The company highlighted clinical progress on its lead oncology candidate, PDS0101, and the initiation of a Phase 2 clinical study by Mayo Clinic. They also strengthened their balance sheet by adding more than $52 million in 2021.
- Achieved milestones in the VERSATILE-002 Phase 2 combination trial of PDS0101-KEYTRUDA® for recurrent and/or metastatic HPV16-associated head and neck cancer.
- Initiated an investigator-initiated trial with Mayo Clinic for patients with HPV-associated oropharyngeal cancer at high risk of recurrence to evaluate PDS0101.
- Announced encouraging preclinical data for the universal flu vaccine, demonstrating a potent neutralization response against multiple strains of the influenza virus.
- Granted U.S. Patent Application for composition of matter and use of PDS0101, extending its U.S. patent protection into 2037.
Headline financials
Revenue & EPS history
PDS Biotechnology · Revenue · Quarterly
$0
Forward guidance
PDS Biotech anticipates a productive 2022, with plans to announce additional data from ongoing Phase 2 oncology trials for PDS0101 and to progress at least one preclinical program, PDS0103, into the clinic.
Tailwinds
- Announce additional data from ongoing Phase 2 oncology trials for PDS0101.
- Progress at least one preclinical program, PDS0103, into the clinic.
- Continue to advance clinical and pre-clinical programs.
- Leverage T-cell activating platforms to advance additional candidates.
- Advance towards full enrollment of 54 patients in the checkpoint inhibitor naïve patient cohort.
Headwinds
- Dependence on additional financing to fund operations and complete development.
- Limited operating history makes it difficult to evaluate prospects.
- The timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune and Infectimune-based product candidates
- The future success of such trials
- Legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.3%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+2.0%
Avg return
30 days after
52%
22 / 42 earnings
Positive
+55.0%
Q3 2022
Best reaction
-27.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.1% | +5.7% | -3.8% | |
| Q3 2025 | -12.2% | -18.2% | +1.0% | |
| Q2 2025 | -4.9% | +0.8% | -5.7% | |
| Q1 2025 | +4.8% | +15.0% | +37.8% | |
| Q4 2024 | +0.8% | -12.9% | +0.8% | |
| Q3 2024 | -27.2% | -24.0% | -33.2% | |
| Q2 2024 | -1.0% | +6.6% | +0.0% | |
| Q1 2024 | -0.3% | -4.4% | -21.2% | |
| Q4 2023 | -11.6% | -10.3% | -27.0% | |
| Q3 2023 | +20.3% | +19.7% | +2.9% | |
| Q2 2023 | +21.2% | +17.1% | +13.2% | |
| Q1 2023 | +5.0% | +14.9% | -7.4% | |
| Q4 2022 | +2.2% | -4.7% | +1.0% | |
| Q3 2022 | +55.0% | +54.5% | +64.3% | |
| Q2 2022 | +0.2% | +1.9% | -21.7% | |
| Q1 2022 | -14.3% | +15.2% | -21.7% | |
| Q4 2021 | -1.1% | -1.0% | -12.1% | |
| Q3 2021 | -1.6% | +2.2% | -14.6% | |
| Q2 2021 | +0.6% | -6.5% | +44.5% | |
| Q1 2021 | +8.2% | +27.0% | +174.1% | |
| Q4 2020 | +1.9% | -5.3% | +2.3% | |
| Q3 2020 | -0.5% | -1.9% | +3.8% | |
| Q2 2020 | -5.1% | +0.7% | -26.5% | |
| Q1 2020 | -2.3% | -1.8% | +39.3% | |
| Q4 2019 | +2.3% | -7.9% | +29.6% | |
| Q3 2019 | +0.0% | -14.0% | -3.4% | |
| Q2 2019 | +1.1% | -0.5% | -15.2% | |
| Q1 2019 | +43.0% | +18.6% | +6.4% | |
| Q4 2018 | +3.8% | +2.6% | -1.7% | |
| Q3 2018 | -2.8% | -4.9% | -6.2% | |
| Q2 2018 | +1.3% | +0.0% | -4.3% | |
| Q1 2018 | -6.4% | -3.6% | -15.3% | |
| Q4 2017 | +1.5% | +9.4% | -92.2% | |
| Q3 2017 | +1.2% | -2.2% | -8.0% | |
| Q2 2017 | -1.2% | -3.1% | -2.0% | |
| Q1 2017 | +2.8% | +2.4% | +3.2% | |
| Q4 2016 | -9.5% | -8.8% | -7.1% | |
| Q3 2016 | -6.3% | -0.6% | +9.9% | |
| Q2 2016 | +1.9% | +0.1% | -4.6% | |
| Q1 2016 | -4.2% | — | — | |
| Q4 2015 | -14.2% | — | — | |
| Q3 2015 | +0.5% | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro